Effects of sertindole on cognition in clozapine-treated schizophrenia patients

Acta Psychiatrica Scandinavica

Volumn 126, Issue 1, 2012, Pages 31-39

  Nielsen, R E ^a,b   Levander, S ^c   Thode, D ^a   Nielsen, J ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b Regional Psychiatric Services West   (Denmark)

^c MALMÖ UNIVERSITY   (Sweden)

Author keywords

Cognition; Randomized controlled trial; Schizophrenia

Indexed keywords

CLOZAPINE; PLACEBO; SERTINDOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84862116009     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2012.01840.x     Document Type: Article

References (63)

1. Szoke A, Trandafir A, Dupont ME, Meary A, Schurhoff F, Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 2008;192:248-257.
2. Hofer A, Biedermann F, Yalcin N, Fleischhacker W. [Neurocognition and social cognition in patients with schizophrenia or mood disorders]. Neuropsychiatr 2010;24:161-169.
3. Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry 2011;45:93-108.
4. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-330.
5. Shamsi S, Lau A, Lencz T et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res 2011;126:257-264.
6. Hofer A, Baumgartner S, Bodner T et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry 2005;20:395-402.
7. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 2011;37:1209-1217.
8. Green MF, Schooler NR, Kern RS et al. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry 2011;168:400-407.
9. Nielsen J, Emborg C, Gydesen S et al. Augmenting Clozapine with Sertindole: a double blinded randomized placebo controlled study. J Clin Psychopharmacol 2011;in press. Accepted for publication.
10. Caspi A, Reichenberg A, Weiser M et al. Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res 2003;65:87-94.
11. Nielsen RE. Cognition in schizophrenia - a systematic review. Drug Discov Today Ther Strateg 2011;8:43-48.
12. Need AC, Attix DK, Mcevoy JM et al. A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB. Hum Mol Genet 2009;18:4650-4661.
13. Chen LS, Rice TK, Thompson PA, Barch DM, Csernansky JG. Familial aggregation of clinical and neurocognitive features in sibling pairs with and without schizophrenia. Schizophr Res 2009;111:159-166.
14. Keefe RS, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004;161:985-995.
15. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-222.
16. Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res 1999;37:1-11.
17. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(Suppl 2):S12-S21.
18. Nielsen RE, Nielsen J. Antipsychotic drug treatment for patients with schizophrenia: theoretical background, clinical considerations and patient preferences. Clin Med Ther 2009;1:1053-1068.
19. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 2010;10:43-57.
20. Davidson M, Galderisi S, Weiser M et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009;166:675-682.
21. Keefe RS, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007;64:633-647.
22. Keefe RS, Sweeney JA, Gu H et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1061-1071.
23. van Veelen NM, Grootens KP, Peuskens J et al. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophr Res 2010;120:191-198.
24. Moore TA, Buchanan RW, Buckley PF et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68:1751-1762.
25. Buchanan RW, Kreyenbuhl J, Kelly DL et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93.
26. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712.
27. Fujii DE, Ahmed I, Jokumsen M, Compton JM. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci 1997;9:240-245.
28. Lindenmayer JP, Iskander A, Park M et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 1998;59:521-527.
29. Krakowski MI, Czobor P, Nolan KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol 2008;28:485-493.
30. Meltzer HY, Bobo WV, Roy A et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008;69:274-285.
31. Delle CR, Salviati M, Fiorentini S, Biondi M. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Exp Clin Psychopharmacol 2007;15:563-568.
32. Bora E, Veznedaroglu B, Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 2005;28:139-141.
33. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000;157:826-828.
34. Freudenreich O, Henderson DC, Macklin EA et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry 2009;70:1674-1680.
35. De LD, Fernandes BS, Berk M et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009;70:1416-1423.
36. Bora E, Yucel M, Pantelis C, Berk M. Meta-analytic review of neurocognition in bipolar II disorder. Acta Psychiatr Scand 2011;123:165-174.
37. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009;119:419-425.
38. Honer WG, Thornton AE, Chen EY et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-482.
39. Akdede BB, Anil Yagcioglu AE, Alptekin K et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 2006;67:1912-1919.
40. Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 2004;18(Suppl 2):19-30.
41. Lindstrom E, Levander S. Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother 2006;7:1825-1834.
42. Thomas SH, Drici MD, Hall GC et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 2010;122:345-355.
43. Gallhofer B, Jaanson P, Mittoux A, Tanghoj P, Lis S, Krieger S. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007;40:275-286.
44. Nielsen J, Graff C, Hardahl T et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 2009;19:702-707.
45. Nielsen J, Andersen MP, Graff C et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 2010;121:385-388.
46. Eberhard J, Levander S, Lindstrom E. Remission in schizophrenia: analysis in a naturalistic setting. Compr Psychiatry 2009;50:200-208.
47. Eberhard J. Schizophrenia in a longitudinal perspective. Lund University, Faculty of Medicine, Doctoral Dissertation Series, 2007; 158
48. Levander S, Jensen J, Grawe R, Tuninger E. Schizophrenia - progressive and massive decline in response readiness by episodes. Acta Psychiatr Scand 2001;104(Suppl 408):65-74.
49. Grawe RW, Levander S. Neuropsychological impairments in patients with schizophrenia: stability and prediction of outcome. Acta Psychiatr Scand 2001;104(Suppl 408):60-64.
50. Stavrou A, Levander S. Data reference and norms of the APT system. Trondheim, Norway: Department of Psychiatry and Behavioural Medicine, University of Trondheim (NTNU), 1987.
51. Lezak M, Howieson D, Loring D. Neuropsychological assessment. New York: Oxford University Press, 2004.
52. Wickens TD. Elementary signal detection theory. New York: Oxford University Press, 2002.
53. Jensen J, Nilsson LL, Levander S. Neurocognitive and psychopathological correlates of self-monitoring ability in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004;254:312-317.
54. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
55. Kay SR, Opler LA, Spitzer RL, Williams JB, Fiszbein A, Gorelick A. SCID-PANSS: two-tier diagnostic system for psychotic disorders. Compr Psychiatry 1991;32:355-361.
56. Rush AJ, Pincus HA, First MB, Blacker D, Endicott J et al. Handbook of psychiatric measures. American Psychiatric Association Publishing: Washington, 2000.
57. Startup M, Jackson MC, Bendix S et al. The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol 2002;41:417-422.
58. Pedersen G, Karterud S. The symptom and function dimensions of the Global Assessment of Functioning (GAF) scale. Compr Psychiatry 2012;53:292-298.
59. Mcgurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999;60(Suppl 12):24-29.
60. Lindstrom E, Eberhard J, Levander S. Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome. Acta Psychiatr Scand 2007;116(Suppl 435):5-16.
61. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000;26:119-136.
62. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988;24:62-67.
63. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand 2011;123:411-422.